Protalix Biotherapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$17,959
$13,474
$3,748
$10,486
Gross Profit
17,959
4,018
1,146
1,630
EBITDA
3,991
-1,586
-4,021
-5,339
EBIT
-1,905
-4,343
-5,652
Net Income
3,236
-2,203
-4,595
-6,044
Net Change In Cash
17,959
13,474
3,748
10,486
Free Cash Flow
4,018
-3,782
3,589
3,345
Cash
27,409
23,399
27,209
23,634
Basic Shares
81,217
73,308
73,036
72,952

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$65,494
$47,638
$38,350
$62,898
Gross Profit
42,512
28,046
22,001
52,025
EBITDA
11,651
-10,782
-18,943
4,450
EBIT
10,460
-11,868
-20,061
3,148
Net Income
8,312
-14,927
-33,985
-14,892
Net Change In Cash
65,494
47,638
38,350
62,898
Free Cash Flow
-2,467
-25,628
-11,744
-26,761
Cash
23,634
17,111
38,985
18,265
Basic Shares
82,424
48,472
44,140
29,148

Earnings Calls

Quarter EPS
2024-09-30
$0.03
2024-06-30
-$0.03
2024-03-31
-$0.06
2023-12-31
-$0.07